A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.